These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19264232)

  • 1. FOXP3 germline polymorphisms are not associated with risk of breast cancer.
    Raskin L; Rennert G; Gruber SB
    Cancer Genet Cytogenet; 2009 Apr; 190(1):40-2. PubMed ID: 19264232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
    Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
    Freedman ML; Penney KL; Stram DO; Riley S; McKean-Cowdin R; Le Marchand L; Altshuler D; Haiman CA
    Cancer Res; 2005 Aug; 65(16):7516-22. PubMed ID: 16103107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in TP53 and risk of breast cancer in a population-based case control study.
    Sprague BL; Trentham-Dietz A; Garcia-Closas M; Newcomb PA; Titus-Ernstoff L; Hampton JM; Chanock SJ; Haines JL; Egan KM
    Carcinogenesis; 2007 Aug; 28(8):1680-6. PubMed ID: 17449902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 haplotype determination in breast cancer.
    Weston A; Pan CF; Ksieski HB; Wallenstein S; Berkowitz GS; Tartter PI; Bleiweiss IJ; Brower ST; Senie RT; Wolff MS
    Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):105-12. PubMed ID: 9037561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between CDH1 haplotypes and gastric cancer risk in a Japanese population.
    Yamada H; Shinmura K; Ikeda S; Tao H; Otani T; Hanaoka T; Tsuneyoshi T; Tsugane S; Sugimura H
    Scand J Gastroenterol; 2007 Dec; 42(12):1479-85. PubMed ID: 17852867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
    Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
    Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study.
    Langsenlehner U; Wolf G; Langsenlehner T; Gerger A; Hofmann G; Clar H; Wascher TC; Paulweber B; Samonigg H; Krippl P; Renner W
    Breast Cancer Res Treat; 2008 May; 109(2):297-304. PubMed ID: 17636397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
    De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Bernard L; Pensotti V; Volorio S; Ravagnani F; Radice P; Peterlongo P
    Cancer Detect Prev; 2008; 32(2):140-3. PubMed ID: 18640791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
    Plourde M; Manhes C; Leblanc G; Durocher F; Dumont M; Sinilnikova O; ; Simard J
    J Mol Endocrinol; 2008 Apr; 40(4):161-72. PubMed ID: 18372405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 genotypes and haplotypes associated with risk of breast cancer.
    Buyru N; Altinisik J; Demokan S; Dalay N
    Cancer Detect Prev; 2007; 31(3):207-13. PubMed ID: 17574348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.
    Gal I; Kimmel G; Gershoni-Baruch R; Papa MZ; Dagan E; Shamir R; Friedman E
    Eur J Cancer; 2006 May; 42(8):1129-34. PubMed ID: 16624550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refinement of the 22q12-q13 breast cancer--associated region: evidence of TMPRSS6 as a candidate gene in an eastern Finnish population.
    Hartikainen JM; Tuhkanen H; Kataja V; Eskelinen M; Uusitupa M; Kosma VM; Mannermaa A
    Clin Cancer Res; 2006 Mar; 12(5):1454-62. PubMed ID: 16533768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTPRJ haplotypes and colorectal cancer risk.
    Toland AE; Rozek LS; Presswala S; Rennert G; Gruber SB
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2782-5. PubMed ID: 18843023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer.
    Setiawan VW; Cheng I; Stram DO; Giorgi E; Pike MC; Van Den Berg D; Pooler L; Burtt NP; Le Marchand L; Altshuler D; Hirschhorn J; Henderson BE; Haiman CA
    Cancer Res; 2006 Dec; 66(24):12019-25. PubMed ID: 17178901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
    Cox DG; Blanché H; Pearce CL; Calle EE; Colditz GA; Pike MC; Albanes D; Allen NE; Amiano P; Berglund G; Boeing H; Buring J; Burtt N; Canzian F; Chanock S; Clavel-Chapelon F; Feigelson HS; Freedman M; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel L; Kraft P; LeMarchand L; Lund E; Palli D; Peeters PH; Riboli E; Stram DO; Thun M; Tjonneland A; Trichopoulos D; Yeager M;
    Breast Cancer Res; 2006; 8(5):R54. PubMed ID: 16987421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ-line HER-2 variant and breast cancer risk by stage of disease.
    McKean-Cowdin R; Kolonel LN; Press MF; Pike MC; Henderson BE
    Cancer Res; 2001 Dec; 61(23):8393-4. PubMed ID: 11731415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity.
    Grossman I; Avidan N; Singer C; Paperna T; Lancet D; Beckmann JS; Miller A
    Genes Immun; 2004 Sep; 5(6):493-504. PubMed ID: 15269719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.